Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up - Time to Buy?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $30.35, but opened at $31.82. Collegium Pharmaceutical shares last traded at $31.35, with a volume of 26,389 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on COLL. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Piper Sandler reiterated a "neutral" rating and set a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday. Finally, Needham & Company LLC restated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $43.75.

Collegium Pharmaceutical Price Performance

The firm has a market capitalization of $1.01 billion, a P/E ratio of 25.88 and a beta of 0.64. The company has a debt-to-equity ratio of 3.30, a current ratio of 1.08 and a quick ratio of 1.01. The company's 50 day moving average price is $29.38 and its 200 day moving average price is $29.53.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 99.08% and a net margin of 6.61%. The company had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. During the same quarter in the prior year, the business earned $1.45 earnings per share. The firm's revenue for the quarter was up 22.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical declared that its board has authorized a stock buyback plan on Monday, July 7th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the business's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the completion of the transaction, the director directly owned 70,658 shares in the company, valued at $2,163,547.96. The trade was a 8.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.51% of the company's stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Collegium Pharmaceutical by 1.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company's stock worth $522,000 after purchasing an additional 339 shares in the last quarter. AlphaQuest LLC increased its holdings in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company's stock worth $366,000 after purchasing an additional 374 shares in the last quarter. Foundry Partners LLC increased its holdings in Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company's stock worth $463,000 after purchasing an additional 381 shares in the last quarter. SummerHaven Investment Management LLC increased its holdings in Collegium Pharmaceutical by 1.9% in the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock worth $727,000 after purchasing an additional 448 shares in the last quarter. Finally, Gallacher Capital Management LLC increased its holdings in Collegium Pharmaceutical by 3.3% in the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company's stock worth $417,000 after purchasing an additional 470 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.